
## Peter Gottlieb

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10942957/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 212-224.	11.4	85
2	Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes. Journal of Translational Autoimmunity, 2021, 4, 100089.	4.0	3
3	Unmethylated Insulin as an Adjunctive Marker of Beta Cell Death and Progression to Type 1 Diabetes in Participants at Risk for Diabetes. International Journal of Molecular Sciences, 2019, 20, 3857.	4.1	9
4	Single-Cell Analysis of CD4 T Cells in Type 1 Diabetes: From Mouse to Man, How to Perform Mechanistic Studies. Diabetes, 2019, 68, 1886-1891.	0.6	6
5	Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. Diabetes, 2019, 68, 1267-1276.	0.6	80
6	Combinatorial detection of autoreactive CD8+ T cells with HLA-A2 multimers: a multi-centre study by the Immunology of Diabetes Society T Cell Workshop. Diabetologia, 2018, 61, 658-670.	6.3	22
7	Abnormal T Cell Frequencies, Including Cytomegalovirus-Associated Expansions, Distinguish Seroconverted Subjects at Risk for Type 1 Diabetes. Frontiers in Immunology, 2018, 9, 2332.	4.8	12
8	ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study. Diabetes Technology and Therapeutics, 2016, 18, 410-414.	4.4	25
9	Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?. Diabetes Care, 2016, 39, 1738-1744.	8.6	19
10	Immune Therapy and $\hat{I}^2$ -Cell Death in Type 1 Diabetes. Diabetes, 2013, 62, 1676-1680.	0.6	73
11	Validity and Reproducibility of Measurement of Islet Autoreactivity by T-Cell Assays in Subjects With Early Type 1 Diabetes. Diabetes, 2009, 58, 2588-2595.	0.6	92
12	Immunotherapy for the Prevention and Treatment of Type 1 Diabetes. Diabetes Care, 2009, 32, 1769-1782.	8.6	71
13	Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5Ayears. Clinical Immunology, 2009, 132, 166-173.	3.2	184
14	Expansion of a unique T cell subset Th40 describes a commonality in type 1 diabetes and MS. FASEB Journal, 2008, 22, 667.26.	0.5	0
15	The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 17040-17045.	7.1	843
16	Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Journal of Autoimmunity, 2003, 21, 365-376.	6.5	81